Export financials
Nabriva Therapeutics plc (NBRV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Nabriva Therapeutics plc Income Statement 2022-2011 | NBRV
Brief overview of financial results at Nabriva Therapeutics plc
The conclusions below are based on five years of reported results. Revenue reported by Nabriva Therapeutics plc was 5.3 million dollars at the beginning of the period and 36.9 million dollars at the end. The cumulative result was +594.4%, corresponding to roughly 47.3% per year. Revenue growth reflects a pronounced phase of business expansion.
EBITDA changed from −$73.3 million to −$55.3 million (+24.6%). EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of −1378.8% and −149.6%. The increased EBITDA share is a positive sign.
The final result was −74.4 million dollars initially and −57.2 million dollars in the final year. The direction improved, yet positive earnings are still absent.
The market value of the business moved from $1.5 billion to $4.1 million, or −99.7%. The market has not yet confirmed the improvement in fundamentals.
What the figures show
Positive developments coexist with areas of weakness. Key strengths include a larger revenue base, higher operating efficiency and a stronger final result. The weaker side of the profile includes lower investor confidence and a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Nabriva Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.1 M | 787 K | 1.23 M | 100 M | 101 M | 1.53 B | 232 M | 95.4 M | - | - | - | - |
Shares |
2.68 M | 1.73 M | 514 K | 7.42 M | 5.08 M | 29.8 M | 2.15 M | 1.06 M | 325 K | - | - | - |
Historical Prices |
1.53 | 0.454 | 2.39 | 13.5 | 19.8 | 51.4 | 108 | 90.1 | - | - | - | - |
Net Income |
-57.2 M | -49.4 M | -69.5 M | -82.8 M | -115 M | -74.4 M | -54.9 M | -47 M | -14.2 M | 15.5 M | - | - |
Revenue |
36.9 M | 28.9 M | 5.03 M | 9.48 M | 9.66 M | 5.32 M | 6.48 M | - | - | - | - | - |
Cost of Revenue |
28.6 M | 13.1 M | 766 K | 70 K | - | - | - | - | - | - | - | - |
Gross Profit |
8.35 M | 15.7 M | 4.26 M | 7.68 M | - | - | - | - | - | - | - | - |
Operating Income |
-55.5 M | -48.5 M | -66.1 M | -79.5 M | -114 M | -73.8 M | -55 M | -27.8 M | -10.7 M | - | - | - |
Interest Expense |
698 K | 901 K | 1.65 M | 3.39 M | 133 K | 43 K | 75 K | 22.1 M | 2.91 M | - | - | - |
EBITDA |
-55.3 M | -48.2 M | -65.7 M | -79.1 M | -114 M | -73.3 M | -54.8 M | -27.6 M | -10.5 M | 28.1 M | - | - |
Operating Expenses |
63.8 M | 64.3 M | 70.4 M | 87.2 M | 31.7 M | 23.4 M | 61.5 M | 31.5 M | 13.1 M | - | - | - |
General and Administrative Expenses |
45.3 M | 51.6 M | 55.3 M | 62.5 M | 41.7 M | 29.5 M | 13.5 M | 7.92 M | 3.74 M | 3.91 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Nabriva Therapeutics plc
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
3.23 M | 3.2 M | 143 K | 2.73 M | 2.53 M | 2.35 M | 164 K | 2.02 M | 40.6 M | 26.4 M | -105 M | 145 M | 113 M | 9.46 M | -64.7 M | 75.2 M | 72.5 M | 68.7 M | -40.3 M | 58.4 M | 40.5 M | 36.9 M | 2.31 M | 28.1 M | 27.2 M | 27.2 M | 2.72 M | 21.3 M | 21.3 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-12.1 M | -8.7 M | -22.8 M | -11.5 M | -11.1 M | -11.8 M | -13.1 M | -10.7 M | -11.8 M | -14 M | -17.8 M | -13 M | -15.4 M | -23.3 M | -23 M | -17.8 M | -21.7 M | -20.2 M | -30.8 M | -52.8 M | -17.8 M | -13.3 M | -22.3 M | -22.3 M | -14.6 M | -15.2 M | -15.2 M | -14 M | -12.1 M | -13.6 M | -7.96 M | -8.42 M | -24.5 M | -6.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
2.24 M | 7.59 M | 10.6 M | 9.15 M | 9.19 M | 8.02 M | 9.26 M | 8.86 M | 8.24 M | 2.53 M | 2.46 M | 1.29 M | 487 K | 789 K | 333 K | 6.92 M | 525 K | 1.7 M | 797 K | 461 K | 847 K | 7.55 M | 1.12 M | 1.47 M | 1.05 M | 1.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
9.07 M | 4.44 M | 16.3 M | 4.42 M | 4.46 M | 3.36 M | 5.27 M | 4.2 M | 3.62 M | 62 K | 365 K | 25 K | 368 K | 8 K | 55 K | 15 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-6.83 M | 3.15 M | -5.78 M | 4.74 M | 4.74 M | 4.66 M | 4 M | 4.66 M | 4.62 M | 2.47 M | 2.1 M | 1.27 M | 119 K | 781 K | 278 K | 6.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-12 M | -8.48 M | -22.3 M | -11.2 M | -10.4 M | -11.6 M | -12.9 M | -10.8 M | -11.4 M | -13.4 M | -18.3 M | -13.2 M | -14.5 M | -20.2 M | -22.1 M | -17.2 M | -21 M | -19.2 M | -30.9 M | -52.9 M | -17.7 M | -12.9 M | -22.3 M | -20.7 M | -15.6 M | -15.2 M | -14.7 M | -14.1 M | -11.5 M | -14.7 M | -10.2 M | -8.33 M | -5.52 M | -3.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1 K | -194 K | 1.13 M | -146 K | -198 K | -215 K | 1.15 M | -221 K | -236 K | -221 K | 573 K | 450 K | -634 K | 798 K | 99 K | -10 K | 56 K | 70 K | -100 K | -54 K | -141 K | 23 K | 101 K | 301 K | 3 K | 22 K | - | 35 K | - | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-12 M | -8.45 M | -22.3 M | -11.2 M | -10.3 M | -11.5 M | -12.8 M | -10.7 M | -11.3 M | -13.3 M | -18.2 M | -13.1 M | -14.3 M | -20.1 M | -21.8 M | -17.3 M | -20.9 M | -19.1 M | -30.8 M | -52.8 M | -17.6 M | -12.7 M | -22.1 M | -20.6 M | -15.5 M | -15.1 M | -14.7 M | -13.9 M | -11.4 M | -14.7 M | -10.2 M | -8.33 M | -5.52 M | -3.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
5.19 M | 11.6 M | 16.6 M | 15.9 M | 15.1 M | 16.2 M | 16.9 M | 15.5 M | 16 M | 15.9 M | 20.4 M | 14.5 M | 14.6 M | 21 M | 22.3 M | 24.1 M | 21.5 M | 20.9 M | 31.7 M | 53.4 M | 18.6 M | 20.4 M | 23.4 M | 22.2 M | 16.6 M | 16.9 M | 17 M | 15 M | 13.3 M | 16.1 M | 11.2 M | 9.62 M | 6.42 M | 4.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.11 M | 9 M | 9.61 M | 11.9 M | 11 M | 12.7 M | 14.5 M | 12.3 M | 12.9 M | 12 M | 17.5 M | 11 M | 10.7 M | 16 M | 17.1 M | 18.5 M | 13.4 M | 13.4 M | 10.2 M | 12.6 M | 8.84 M | 10.1 M | 10.2 M | 9.52 M | 5.57 M | 4.22 M | - | 2.99 M | 3.37 M | 3.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Nabriva Therapeutics plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.